


# Formal Synthesis of Pseudolaric Acid B

Naoki Mori\* 

Research Foundation ITSUU Laboratory, C1232 Kanagawa Science Park R & D Building, 3-2-1 Sakado, Takatsu-ku, Kawasaki, Kanagawa 213-0012, Japan  
nmori@itsuu.or.jp



Received: 28.12.2019

Accepted after revision: 02.02.2020


Published online: 18.02.2020

DOI: 10.1055/s-0039-1690829; Art ID: st-2019-u0701-l

**Abstract** A formal synthesis of pseudolaric acid B, a diterpene isolated from the root bark of *Pseudolarix kaempferi* Gordon (Pinaceae), to Trost's synthetic intermediate was achieved in 17 steps from a known ketone. Key features of this synthesis include a Claisen rearrangement and iodoetherification to construct quaternary stereocenters and ring-closing metathesis to form the seven-membered ring.

**Key words** pseudolaric acid B, total synthesis, diterpenes, cytotoxins, Claisen rearrangement, iodoetherification

More than 20 natural pseudolaric acids, including pseudolaric acids A (**1**) and B (**2**), have been isolated from the root bark of *Pseudolarix kaempferi* Gordon (Pinaceae) (Figure 1).<sup>1</sup> Among the members of this family, pseudolaric acid B (**2**) has significant medical potential, exhibiting potent antifungal, antifertility, and cytotoxic activities, even against multidrug-resistant cancer cell lines. These latter activities suggest that **2** might function as a potential lead for new anticancer agents. Structurally, pseudolaric acids A (**1**) and B (**2**) feature a distinctive tricyclic core with an unusual *trans*-fused [5–7] ring system. The complicated structures, as well as the important biological properties, of pseudolaric acids have fascinated both biochemists and synthetic chemists. In fact, Mafu et al.<sup>2</sup> recently identified an enzyme involved in the biosynthetic pathway of **2**, and two total syntheses of **1** by Chiu and co-workers<sup>3</sup> [26 steps for (–)-**1**] and Yang and co-workers<sup>4</sup> [16 steps for (±)-**1**], and one total synthesis of **2** by Trost et al.<sup>5</sup> [28 steps for (–)-**2**] have been reported. We previously attempted to improve on the synthesis of **2** by using a Dieckmann condensation as the key step to construct its *trans*-fused core framework.<sup>6</sup> Here, we describe a formal synthesis of **2** by using a new synthetic strategy.





**Figure 1** Structures of pseudolaric acids A (**1**) and B (**2**)

We previously synthesized model compound **9**, containing the *trans*-fused bicyclic core of **2**, in 20 steps, starting from the known compound **3'** (Scheme 1a).<sup>6</sup> However, the yield of the radical coupling reaction **4** → **5** was quite low due to undesirable side reactions; i.e., a 1,6-hydrogen shift to generate compound **6**, and a direct reduction by Bu<sub>3</sub>SnH to generate compound **7**. To overcome these disadvantages, we designed an alternative approach for the synthesis of **2** (Scheme 1b). Pseudolaric acid B (**2**) can be accessed from Trost's intermediate **10** in six steps; we therefore chose **10** as our synthetic goal. Based on our retrosynthetic analysis, the seven-membered ring of **10** might be constructed through a ring-closing metathesis (RCM) reaction of diene **11**, obtained by a reductive opening of the tetrahydrofuran ring of the iodo ester **12**. Installation of an unsaturated ester side chain onto **12** might be achieved through a radical coupling of iodo alcohol **14** with the allylstannane **13**.<sup>8</sup> We expected that this Keck radical allylation, which proceeds in the absence of Bu<sub>3</sub>SnH, would be effective in increasing the yield of the desired product. Compound **14** might be prepared from the known starting material **15**,<sup>9</sup> in which a TIPS protecting group replaces the previously employed Bn group to avoid the presence of troublesome benzylic hydrogens.

Our synthesis commenced with the preparation of aldehyde **22** (Scheme 2). Methoxycarbonylation of **15** provided a diastereomeric mixture of esters **16** (dr = 2:1), which were

converted into the enol triflate **17** in 78% yield. Because a Stille-type coupling<sup>10</sup> of **17** with  $\text{Bu}_3\text{SnCH}_2\text{OPMB}^{11}$  was unsuccessful, we installed a hydroxymethyl group through palladium-catalyzed carboxylation<sup>12</sup> and subsequent reduction to afford the alcohol **20** in 65% yield over two steps. After the formation of a vinyl ether of alcohol **20**, Claisen rearrangement of the resultant product **21** in refluxing DMF for one hour gave aldehyde **22** [50%; quantitative based on recovered starting material (brsm)] in a 3.3:1 diastereomeric ratio, which was consistent with our previous results.<sup>6</sup> Note that longer reaction times adversely affect the yield of **22**, owing to its decomposition in refluxing DMF (14% after 6 h).



We next sought to prepare diene **11**, beginning with the introduction of a hydroxymethyl group onto aldehyde **22** (Scheme 3). Unfortunately, the addition of  $\text{LiCH}_2\text{OPMB}$  to **22**



resulted in the formation of lactone **23**. Therefore, **22** was first converted into the diene **25**, which could be obtained as a single diastereomer about the quaternary center following separation by column chromatography on silica gel. Diene **25** was then dihydroxylated with  $\text{OsO}_4$  under neutral conditions to afford diol **26** as a 1:1 mixture of diastereomers in good yield (96%). The next step of the reaction, the iodoetherification of **26**, required optimization with respect to the solvent. For example, treatment of **26** with NIS in MeCN afforded the desired product **14** ( $\text{dr} = 1:1$ ) in 78% yield, whereas the use of  $\text{CH}_2\text{Cl}_2$  resulted in the oxidative cleavage of the 1,2-diol to regenerate aldehyde **22** in 51% yield. For the installation of the unsaturated ester side chain, **14** was treated with the allylstannane **13**<sup>8</sup> and AIBN in refluxing benzene to afford alcohol **27** ( $\text{dr} = 1:1$ ) in 59% yield. After iodination of alcohol **27** under Appel's conditions, the tetrahydrofuran ring of iodide **12** was reductively opened by treatment with Zn in EtOH at 60 °C to afford diene **11** as a single diastereomer in 82% yield.

The formal synthesis of **2** was accomplished by first subjecting **11** to RCM conditions, using the Grubbs second-generation catalyst, to construct the seven-membered ring of **28**<sup>13</sup> in 86% yield (Scheme 4). The TIPS protecting group was then removed with TBAF/AcOH, giving alcohol **29** in 54% yield with 34% of unreacted **28** remaining. Note that in the absence of AcOH, the reaction was dominated by 1,4-addition of the tertiary alcohol to the unsaturated ester. After oxidation to the aldehyde **30**, nucleophilic addition of a methyl group was attempted. Unfortunately, the standard conditions proved fruitless ( $\text{MeLi}$ , THF,  $-78$  °C: decomposition;  $\text{MeMgBr}$ , THF,  $-78$  °C: no reaction). Trost et al.<sup>5</sup> report-

ed that an organocerium reagent served as an excellent nucleophile in a similar transformation. To our delight, treatment of **30** with  $\text{MeCeCl}_2$ <sup>14</sup> followed by Dess–Martin oxidation successfully afforded Trost's intermediate **10**, in racemic form, from which pseudolaric acid B (**2**) has been obtained in six steps, thus completing a formal synthesis of



**2**. The <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra of compound **10** prepared in this work agreed with those reported by the Trost group.

In conclusion, we have accomplished a formal synthesis of pseudolaric acid B (**2**) from the known ketone **15** to Trost's synthetic intermediate **10** in 17 steps (six more steps are required to obtain **2**). The key elements in the present synthesis include: (1) construction of the vicinal quaternary stereocenters via a Claisen rearrangement (**21** → **22**) and stereoselective iodoetherification (**26** → **14**) and (2) formation of the seven-membered ring through an RCM reaction (**11** → **28**). This current synthesis is more efficient than our previous preparation,<sup>6</sup> and could expand the opportunities for derivatization of pseudolaric acid B and related compounds as lead anticancer drugs by using (*S*)-2-(hydroxymethyl)cyclopentan-1-one<sup>15</sup> as a chiral substrate.

## Funding Information

This work was supported by Grant-in-Aid for Scientific Research (C) from the Japan Society for the Promotion of Science (Grant Number 16K07712).

## Acknowledgment

I am grateful to Professor Masayuki Inoue (The University of Tokyo), Professor Hidenori Watanabe (The University of Tokyo), and Professor Hirosato Takikawa (The University of Tokyo) for their kind and helpful discussions. I thank Professor Shuji Akai (Osaka University), Professor Takeo Kawabata (Kyoto University), Professor Tomohiko Ohwada (The University of Tokyo), Dr. Mitsuaki Ohtani (ITSUU Laboratory), and Dr. Kin-ichi Tadano (ITSUU Laboratory) for their helpful discussions throughout this work. I also thank Mr. Yoshihisa Akamatsu (The University of Tokyo) for the preparation of the starting material **15**.

## Supporting Information

Supporting information for this article is available online at <https://doi.org/10.1055/s-0039-1690829>.

## References and Notes

- Chiu, P.; Leung, L. T.; Ko, B. C. B. *Nat. Prod. Rep.* **2010**, *27*, 1066.
- Mafu, S.; Karunanithi, P. S.; Palazzo, T. A.; Harrod, B. L.; Rodriguez, S. M.; Mollhoff, I. N.; O'Brien, T. E.; Tong, S.; Fiehn, O.; Tantillo, D. J.; Bohlmann, J.; Zerbe, P. *Proc. Natl. Acad. Sci. U.S.A.* **2017**, *114*, 974.
- Geng, Z.; Chen, B.; Chiu, P. *Angew. Chem. Int. Ed.* **2006**, *45*, 6197.
- Xu, T.; Li, C.-C.; Yang, Z. *Org. Lett.* **2011**, *13*, 2630.
- (a) Trost, B. M.; Waser, J.; Meyer, A. *J. Am. Chem. Soc.* **2007**, *129*, 14556. (b) Trost, B. M.; Waser, J.; Meyer, A. *J. Am. Chem. Soc.* **2008**, *130*, 16424.
- Mori, N.; Mase, C.; Watanabe, H.; Takikawa, H. *Tetrahedron Lett.* **2018**, *59*, 2600.
- Mittendorf, J.; Kunisch, F.; Matzke, M.; Militzer, H.-C.; Schmidt, A.; Schönfeld, W. *Bioorg. Med. Chem. Lett.* **2003**, *13*, 433.

- (8) Baldwin, J. E.; Adlington, R. M.; Birch, D. J.; Crawford, J. A.; Sweeney, J. B. *J. Chem. Soc., Chem. Commun.* **1986**, 1339.
- (9) Sano, S.; Matsumoto, T.; Nakao, M. *Tetrahedron Lett.* **2014**, *55*, 4480.
- (10) (a) Cook, G. K.; Hornback, W. J.; Jordan, C. L.; McDonald, J. H. III.; Munroe, J. E. *J. Org. Chem.* **1989**, *54*, 5828. (b) Chen, X.-T.; Bhattacharya, S. K.; Zhou, B.; Gutteridge, C. E.; Pettus, T. R. R.; Danishefsky, S. J. *J. Am. Chem. Soc.* **1999**, *121*, 6563.
- (11) Semmelhack, M. F.; Gu, Y.; Ho, D. M. *Tetrahedron Lett.* **1997**, *38*, 5583.
- (12) Yoshimitsu, T.; Arano, Y.; Kaji, T.; Ino, T.; Nagaoka, H.; Tanaka, T. *Heterocycles* **2009**, *77*, 179.
- (13) **Dimethyl 8a-Hydroxy-1-[[triisopropylsilyloxy]methyl]-2,3,4,7,8,8a-hexahydroazulene-3a,6(1H)-dicarboxylate (28)**  
A mixture of diene **11** (16.4 mg, 34.0  $\mu\text{mol}$ ) and the Grubbs second-generation catalyst (2.9 mg, 3.42  $\mu\text{mol}$ ) in benzene (1.5 mL) was refluxed for 5 h, then cooled to rt. The mixture was then concentrated under reduced pressure, and the residue was purified by preparative TLC (hexane–EtOAc, 5:1) to give a colorless oil; yield: 13.3 mg (86%). IR (film): 3515, 2945, 2866, 1716, 1463, 1238, 1194, 1055, 882, 755, 681  $\text{cm}^{-1}$ .  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  = 6.96 (m, 1 H), 4.00 (dd,  $J$  = 9.6, 6.4 Hz, 1 H), 3.70 (s, 3 H), 3.59 (m, 1 H), 3.58 (s, 3 H), 2.85 (m, 1 H), 2.76 (m, 1 H), 2.58–2.45 (m, 2 H), 2.37 (dt,  $J$  = 2.8, 14.0 Hz, 1 H), 2.20 (m, 1 H), 2.08–1.85 (m, 4 H), 1.23 (m, 1 H), 1.12–1.00 (m, 21 H).  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  = 174.64, 168.53, 140.74, 135.51, 82.74, 65.29, 58.91, 57.38, 51.88, 51.55, 34.71, 30.39, 29.82, 26.00, 20.35, 18.06, 11.97. HRMS (ESI):  $m/z$  [ $\text{M} + \text{Na}$ ] $^+$  calcd for  $\text{C}_{24}\text{H}_{42}\text{NaO}_6\text{Si}$ : 477.2643; found: 477.2637.
- (14) Imamoto, T.; Sugiura, Y.; Takiyama, N. *Tetrahedron Lett.* **1984**, *25*, 4233.
- (15) Mase, N.; Inoue, A.; Nishio, M.; Takabe, K. *Bioorg. Med. Chem. Lett.* **2009**, *19*, 3955.